$URGN
UroGen Pharma Ltd.

2019 Q4 Form 10-Q Financial Statement

#000156459019042553 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $0.00 $0.00 $283.0K
YoY Change -100.0% -96.38%
Cost Of Revenue $0.00 $0.00 $1.055M
YoY Change -100.0% 251.67%
Gross Profit $0.00 $0.00 -$772.0K
YoY Change -100.0% -110.27%
Gross Profit Margin -272.79%
Selling, General & Admin $19.75M $13.97M $10.74M
YoY Change 57.37% 30.07% 388.18%
% of Gross Profit
Research & Development $20.09M $9.481M $9.574M
YoY Change 75.15% -0.97% 70.36%
% of Gross Profit
Depreciation & Amortization $110.0K $100.0K $100.0K
YoY Change 57.14% 0.0% 400.0%
% of Gross Profit
Operating Expenses $39.84M $23.45M $20.32M
YoY Change 65.88% 15.44% 159.81%
Operating Profit -$39.84M -$23.45M -$21.09M
YoY Change 65.88% 11.21% 6860.07%
Interest Expense $1.010M $1.260M $560.0K
YoY Change 83.64% 125.0% 5500.0%
% of Operating Profit
Other Income/Expense, Net -$140.0K -$60.00K
YoY Change 16.67%
Pretax Income -$38.97M -$22.25M -$20.53M
YoY Change 65.2% 8.38% 6743.33%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$38.97M -$22.25M -$20.53M
YoY Change 64.33% 8.37% 6790.27%
Net Earnings / Revenue -7255.48%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.856M -$1.064M -$1.276M
COMMON SHARES
Basic Shares Outstanding 20.98M 20.90M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.1M $158.2M $109.5M
YoY Change 45.19% 44.47% 38.26%
Cash & Equivalents $49.69M $66.15M $109.5M
Short-Term Investments $97.39M $92.05M $0.00
Other Short-Term Assets $1.500M $1.700M $1.900M
YoY Change 50.0% -10.53% 72.73%
Inventory $0.00
Prepaid Expenses
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $148.6M $159.9M $111.5M
YoY Change 45.37% 43.39% 38.68%
LONG-TERM ASSETS
Property, Plant & Equipment $977.0K $893.0K $1.000M
YoY Change 3.06% -10.7% 42.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $48.60M $63.50M
YoY Change
Other Assets $264.0K $2.423M $100.0K
YoY Change -16.72% 2323.0%
Total Long-Term Assets $53.75M $66.88M $1.100M
YoY Change 3984.65% 5979.73% 37.5%
TOTAL ASSETS
Total Short-Term Assets $148.6M $159.9M $111.5M
Total Long-Term Assets $53.75M $66.88M $1.100M
Total Assets $202.4M $226.8M $112.6M
YoY Change 95.43% 101.38% 38.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.694M $2.638M $6.300M
YoY Change 9.88% -58.13% 80.0%
Accrued Expenses $14.80M $11.50M $2.700M
YoY Change 202.04% 325.93% 145.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.48M $14.09M $9.000M
YoY Change 44.69% 56.53% 83.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.600M $1.700M
YoY Change
Total Long-Term Liabilities $2.600M $1.749M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $19.48M $14.09M $9.000M
Total Long-Term Liabilities $2.600M $1.749M $0.00
Total Liabilities $22.09M $15.84M $9.000M
YoY Change 64.03% 75.97% 83.67%
SHAREHOLDERS EQUITY
Retained Earnings -$228.0M -$189.0M
YoY Change 85.52%
Common Stock $408.0M $57.00K
YoY Change 91.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $180.3M $210.9M $103.6M
YoY Change
Total Liabilities & Shareholders Equity $202.4M $226.8M $112.6M
YoY Change 95.43% 101.38% 38.67%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$38.97M -$22.25M -$20.53M
YoY Change 64.33% 8.37% 6790.27%
Depreciation, Depletion And Amortization $110.0K $100.0K $100.0K
YoY Change 57.14% 0.0% 400.0%
Cash From Operating Activities -$26.00M -$12.53M -$9.280M
YoY Change 152.92% 35.02% -456.92%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$50.00K -$340.0K
YoY Change 900.0% -85.29% 1600.0%
Acquisitions
YoY Change
Other Investing Activities $9.490M -$12.61M $0.00
YoY Change -100.0%
Cash From Investing Activities $9.300M -$12.66M -$340.0K
YoY Change -46600.0% 3623.53% 183.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.0K 1.130M -20.00K
YoY Change -89.09% -5750.0% -95.0%
NET CHANGE
Cash From Operating Activities -26.00M -12.53M -9.280M
Cash From Investing Activities 9.300M -12.66M -340.0K
Cash From Financing Activities 240.0K 1.130M -20.00K
Net Change In Cash -16.46M -24.06M -9.640M
YoY Change 103.21% 149.59% -563.46%
FREE CASH FLOW
Cash From Operating Activities -$26.00M -$12.53M -$9.280M
Capital Expenditures -$200.0K -$50.00K -$340.0K
Free Cash Flow -$25.80M -$12.48M -$8.940M
YoY Change 151.46% 39.6% -441.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66147000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
523000
CY2018Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
253000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1160000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
159876000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
893000
CY2019Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
55000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
63506000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2423000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
672000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
102243000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
948000
CY2018Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
51000
dei Entity Central Index Key
EntityCentralIndexKey
0001668243
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20979580
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
768-9780
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Security12b Title
Security12bTitle
Ordinary Shares, par value NIS 0.01 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101318000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
92046000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53163000
CY2019Q3 urgn Interest And Other Income Expenses Net
InterestAndOtherIncomeExpensesNet
1201000
CY2018Q3 urgn Interest And Other Income Expenses Net
InterestAndOtherIncomeExpensesNet
556000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-22252000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69639000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20916780
us-gaap Net Income Loss
NetIncomeLoss
-51940000
us-gaap Net Income Loss
NetIncomeLoss
-66173000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1124000
us-gaap Net Income Loss
NetIncomeLoss
-51940000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7243000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38079
dei Entity Registrant Name
EntityRegistrantName
UROGEN PHARMA LTD.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1460746
dei Entity Address Address Line1
EntityAddressAddressLine1
499 Park Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10004
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-20533000
us-gaap Net Income Loss
NetIncomeLoss
-66173000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
303000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20533000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51940000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-22252000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65870000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27019000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64221000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109483000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
317000
CY2019Q3 us-gaap Assets
Assets
226753000
CY2018Q4 us-gaap Assets
Assets
103559000
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7880000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8540000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5082000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4925000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1126000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14088000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13465000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1749000
CY2019Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1749000
CY2019Q3 us-gaap Liabilities
Liabilities
15837000
CY2018Q4 us-gaap Liabilities
Liabilities
13465000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20944250
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20944250
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16214883
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16214883
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
57000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
399600000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
212921000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189044000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122871000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
303000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
210916000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
90094000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
226753000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103559000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
283000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1128000
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
1055000
us-gaap Cost Of Revenue
CostOfRevenue
1803000
CY2018Q3 us-gaap Gross Profit
GrossProfit
-772000
us-gaap Gross Profit
GrossProfit
18000
us-gaap Gross Profit
GrossProfit
-675000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9481000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9574000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29203000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25469000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13972000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10743000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40454000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23453000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21089000
urgn Interest And Other Income Expenses Net
InterestAndOtherIncomeExpensesNet
3466000
urgn Interest And Other Income Expenses Net
InterestAndOtherIncomeExpensesNet
1323000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-100000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-20533000
us-gaap Net Income Loss
NetIncomeLoss
-51940000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.30
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16092583
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20373070
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15721445
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22230000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
224779000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-22252000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
210916000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
113551000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1050000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9515000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-20533000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
90094000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3343000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21902000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161447000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
303000
us-gaap Net Income Loss
NetIncomeLoss
-66173000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
68515000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1050000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21765000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64193000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
103583000
us-gaap Net Income Loss
NetIncomeLoss
-66173000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
188000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
349000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
497000
us-gaap Share Based Compensation
ShareBasedCompensation
21902000
us-gaap Share Based Compensation
ShareBasedCompensation
21765000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-100000
urgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
736000
urgn Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
620000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-316000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
112000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
520000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-329000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-190000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2058000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-650000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
157000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
734000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45017000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27050000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
52000
urgn Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
168852000
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-35901000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14100000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
536000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-154889000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35313000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3343000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161662000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64221000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165005000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34901000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72484000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
101571000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36999000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66670000
urgn Non Cash Exercise Of Stock Options
NonCashExerciseOfStockOptions
1050000
us-gaap Nature Of Operations
NatureOfOperations
<p id="NOTE_1BUSINESS_NATURE_OPERATIONS" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1-BUSINESS AND NATURE OF OPERATIONS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4<span style="letter-spacing:0.45pt;"> </span>(“UPL”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016<span style="letter-spacing:0.45pt;"> </span>(“UPI”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>“Company”)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>clinical<span style="letter-spacing:0.55pt;"> </span>stage<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, preparing for the potential commercial launch of its lead product candidates, UGN-101 and UGN-102 and raising capital to support and expand these activities.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p>
urgn Entity Incorporation Date Of Incorporation Month And Year
EntityIncorporationDateOfIncorporationMonthAndYear
2004-04
urgn Operations Commenced Date Month And Year
OperationsCommencedDateMonthAndYear
2016-02
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2-BASIS OF PRESENTATION</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to state fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly-owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and has an accumulated deficit of $189.0 million and $122.9 million as of September 30, 2019 and December 31, 2018, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it expands its portfolio and engages in further research and development activities, particularly conducting nonclinical studies, clinical trials and <span style="Background-color:#FFFFFF;color:#000000;">preparing for the potential commercial launch of its lead product candidates, UGN-101 and UGN-102</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on its ability to develop its technologies to the point of U.S. Food and Drug Administration (<span style="color:#000000;">“</span>FDA<span style="color:#000000;">”</span>) approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these efforts. Based on management’s cash flow projections, the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. However, in the future, the Company may need to raise additional capital to finance the continued operating and capital requirements of the Company. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. If the Company cannot obtain adequate working capital, it may be forced to reevaluate its planned business operations.</p>
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189000000.0
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>most<span style="letter-spacing:0.4pt;"> </span>significant<span style="letter-spacing:0.8pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>relate<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>timing<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue<span style="letter-spacing:0.65pt;"> </span>recognition.</p>
CY2019Q3 urgn Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
221700000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-100000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">’</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">’</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p>
urgn Other Finance Expenses Income
OtherFinanceExpensesIncome
-63000
urgn Finance Income Expense Net
FinanceIncomeExpenseNet
3466000
urgn Finance Income Expense Net
FinanceIncomeExpenseNet
1323000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2638000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4272000
CY2019Q3 urgn Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
804000
CY2018Q4 urgn Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
673000
CY2019Q3 urgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2239000
CY2018Q4 urgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
780000
CY2019Q3 urgn Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
1468000
CY2018Q4 urgn Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
1029000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1786000
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7880000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8540000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3610000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1386000
urgn Other Finance Expenses Income
OtherFinanceExpensesIncome
-144000
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
161777000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
328000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
162080000
CY2019Q3 urgn Debt Securities Available For Sale Unrealized Gain Position
DebtSecuritiesAvailableForSaleUnrealizedGainPosition
300000
CY2019Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
20900000
CY2019Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
14
CY2019Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
98574000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
89965000
CY2019Q3 urgn Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
63506000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
162080000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
89965000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
929000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1819000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1695000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
926000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
747000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
893000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
948000
CY2019Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
UPL signed an addendum to its November 2014 lease agreement for the Company’s principal executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.
CY2019Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
urgn Lessee Operating Lease Extended Lease Expiration Date Month And Year
LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear
2022-08
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
298000
us-gaap Operating Lease Cost
OperatingLeaseCost
901000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
22000
us-gaap Variable Lease Cost
VariableLeaseCost
81000
CY2019Q3 us-gaap Lease Cost
LeaseCost
320000
us-gaap Lease Cost
LeaseCost
982000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3022000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2423000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2429000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1749000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1126000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Payments
OperatingLeasePayments
846000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3159000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M19D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0724
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
323000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1282000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
711000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
528000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
301000
CY2019Q3 urgn Lessee Operating Lease Liability Payments Due Year Six And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter
58000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3203000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
328000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2875000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1136000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1251000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
676000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
567000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
301000
CY2018Q4 urgn Operating Leases Future Minimum Payments Due In Six Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter
58000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3989000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1200000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16200000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000.0
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000.0
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20900000
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20900000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16200000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7243000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9515000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21902000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21765000
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
54600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y

Files In Submission

Name View Source Status
0001564590-19-042553-index-headers.html Edgar Link pending
0001564590-19-042553-index.html Edgar Link pending
0001564590-19-042553.txt Edgar Link pending
0001564590-19-042553-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
urgn-10q_20190930.htm Edgar Link pending
urgn-10q_20190930_htm.xml Edgar Link completed
urgn-20190930.xsd Edgar Link pending
urgn-20190930_cal.xml Edgar Link unprocessable
urgn-20190930_def.xml Edgar Link unprocessable
urgn-20190930_lab.xml Edgar Link unprocessable
urgn-20190930_pre.xml Edgar Link unprocessable
urgn-ex311_8.htm Edgar Link pending
urgn-ex312_9.htm Edgar Link pending
urgn-ex321_6.htm Edgar Link pending
urgn-ex322_7.htm Edgar Link pending